PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2. (November 2022)
- Record Type:
- Journal Article
- Title:
- PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2. (November 2022)
- Main Title:
- PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2
- Authors:
- Fu, Jing
Li, Li
Chen, Long
Su, Congping
Feng, Xiuling
Huang, Kai
Zhang, Laxi
Yang, Xiaoyan
Fu, Qin - Abstract:
- Abstract: Inflammation plays a central role in the development of heart failure. Prostaglandin E2 (PGE2) is a key mediator of the inflammatory process in the cardiovascular system. However, the role of PGE2 in heart failure is complex and controversial. A recent report suggested that PGE2 inhibits acute β adrenergic receptor (β-AR) stimulation-enhanced cardiac contractility. The aim of this study was to characterize the influence of PGE2 on chronic β-AR stimulation-induced heart failure. Male C57BL/6 J mice received isoproterenol (ISO) or vehicle for 4 weeks. PGE2 significantly reversed ISO-induced cardiac contractile dysfunction and remodeling. Mechanically, ventricular myocytes were found to be an important source of TGF-β1 in ISO-model and PGE2 ablated TGF-β1 synthesis in cardiomyocytes through inhibition of β-AR activated PKA-CREB signaling. Furthermore, PGE2 significantly suppressed TGF-β1-GRK2 crosstalk-induced pro-hypertrophy and pro-fibrotic signaling in cardiomyocytes and cardiac fibroblasts, respectively. Pharmacological inhibition of GRK2 also attenuated contractile dysfunction and cardiac hypertrophy and fibrosis in ISO-model. These studies elucidate a novel mechanism by which PGE2 reduces TGF-β1 synthesis and its downstream signaling in heart failure and identify PGE2 or TGF-β1-GRK2 crosstalk as plausible therapeutic targets for preventing or treating heart failure induced by chronic β-AR stimulation. Graphical abstract: Unlabelled Image Highlights: VentricularAbstract: Inflammation plays a central role in the development of heart failure. Prostaglandin E2 (PGE2) is a key mediator of the inflammatory process in the cardiovascular system. However, the role of PGE2 in heart failure is complex and controversial. A recent report suggested that PGE2 inhibits acute β adrenergic receptor (β-AR) stimulation-enhanced cardiac contractility. The aim of this study was to characterize the influence of PGE2 on chronic β-AR stimulation-induced heart failure. Male C57BL/6 J mice received isoproterenol (ISO) or vehicle for 4 weeks. PGE2 significantly reversed ISO-induced cardiac contractile dysfunction and remodeling. Mechanically, ventricular myocytes were found to be an important source of TGF-β1 in ISO-model and PGE2 ablated TGF-β1 synthesis in cardiomyocytes through inhibition of β-AR activated PKA-CREB signaling. Furthermore, PGE2 significantly suppressed TGF-β1-GRK2 crosstalk-induced pro-hypertrophy and pro-fibrotic signaling in cardiomyocytes and cardiac fibroblasts, respectively. Pharmacological inhibition of GRK2 also attenuated contractile dysfunction and cardiac hypertrophy and fibrosis in ISO-model. These studies elucidate a novel mechanism by which PGE2 reduces TGF-β1 synthesis and its downstream signaling in heart failure and identify PGE2 or TGF-β1-GRK2 crosstalk as plausible therapeutic targets for preventing or treating heart failure induced by chronic β-AR stimulation. Graphical abstract: Unlabelled Image Highlights: Ventricular myocytes are important source of TGF-β1 in chronic Isoproterenol (ISO)-induced heart failure. TGF-β1-GRK2 crosstalk in cardiomyocytes and cardiac fibroblasts promotes cardiac hypertrophy and fibrosis. PGE2 reverses ISO-induced heart failure by inhibiting TGF-β1 secretion from cardiomyocytes. PGE2 reverses ISO-induced heart failure by disrupting TGF-β1-GRK2 crosstalk in cardiomyocytes and cardiac fibroblasts. GRK2 inhibitor paroxetine ameliorates ISO-induced cardiac hypertrophy and fibrosis. GRK2 inhibitor paroxetine ameliorates ISO-induced cardiac hypertrophy and fibrosis. … (more)
- Is Part Of:
- Journal of molecular and cellular cardiology. Volume 172(2022)
- Journal:
- Journal of molecular and cellular cardiology
- Issue:
- Volume 172(2022)
- Issue Display:
- Volume 172, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 172
- Issue:
- 2022
- Issue Sort Value:
- 2022-0172-2022-0000
- Page Start:
- 63
- Page End:
- 77
- Publication Date:
- 2022-11
- Subjects:
- PGE2 -- Heart failure -- β adrenergic signaling -- TGF-β1 -- GRK2 -- Remodeling
PGE2 prostaglandin E2 -- COXs cyclooxygenases -- EP E-prostanoid -- β-AR β adrenergic receptor -- TGF-β1 transforming growth factor-β1 -- ISO isoproterenol -- NRVMs neonatal rat left ventricular myocytes -- NRCFs neonatal rat left ventricular fibroblasts -- WGA wheat germ agglutinin -- qRT-PCR quantitative real-time polymerase chain reaction -- ELISA enzyme-linked immunosorbent assay -- FBS fetal bovine serum -- CREB cAMP-responsive element binding protein
Cardiology -- Periodicals
Heart Diseases -- Periodicals
Molecular Biology -- Periodicals
Cardiologie -- Périodiques
Cardiology
Electronic journals
Periodicals
616.12 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00222828 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00222828 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/00222828 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.yjmcc.2022.07.012 ↗
- Languages:
- English
- ISSNs:
- 0022-2828
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5020.690000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24236.xml